TY - JOUR
T1 - Impact of Rituximab and IPI on survival in diffuse large B cell lymphoma patients treated at a tertiary level cancer centre in Pakistan
T2 - A single-centre experience
AU - Athar, Sohail
AU - Siddiqui, Neelam
AU - Rai, Sulaman Raza
AU - Muzaffar, Narjis
AU - Hameed, Abdul
N1 - Publisher Copyright:
© Pakistan Medical Association. All rights reserved.
PY - 2015
Y1 - 2015
N2 - Objective: To determine the impact of Rituximab and international prognostic index score on survival in diffuse large B-cell lymphoma patients. Method: The retrospective study was conducted at Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore, fromJanuary to May 2013 and comprised record of patients with diffuse large B-cell lymphoma who were treated from2007 to 2010. Baseline international prognostic index score, stage at presentation were noted and the records were divided into two groups A and B on the basis of the type of chemotherapy. SPSS 19 was used for statistical analysis. Results: Of the 93 patients in the study whose records were reviewed, 54(58%) were men. Overall median age was 43 years (range: 18-76). Stages at presentation were stage-I 14 (15.1%), stage-II 41 (44.1%), stage-III 20 (21.5%) and stage-IV 18 (19.4%). International prognostic index risk categorisation was low risk 59(63.4%), low intermediate risk 23(24.7%), high intermediate risk 10(10.8%) and high risk 1(1.1%). There were 31(33%) patients in Group A and 62(67%) in Group B. Median follow-up was 3.9 years (range: 1.2-6.1). Overall survival at 4 years was 66.4%; for Group A 65.3% and for Group B 66.7% (p<0.4). On the basis of risk categories, overall survival was statistically significant (p<0.001) between the groups. Conclusion: International prognostic index risk categorisation had statistically significant impact on survival. However, there was no evidence of a significant survival benefit between types of chemotherapy. Further controlled trials are needed in this regard.
AB - Objective: To determine the impact of Rituximab and international prognostic index score on survival in diffuse large B-cell lymphoma patients. Method: The retrospective study was conducted at Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore, fromJanuary to May 2013 and comprised record of patients with diffuse large B-cell lymphoma who were treated from2007 to 2010. Baseline international prognostic index score, stage at presentation were noted and the records were divided into two groups A and B on the basis of the type of chemotherapy. SPSS 19 was used for statistical analysis. Results: Of the 93 patients in the study whose records were reviewed, 54(58%) were men. Overall median age was 43 years (range: 18-76). Stages at presentation were stage-I 14 (15.1%), stage-II 41 (44.1%), stage-III 20 (21.5%) and stage-IV 18 (19.4%). International prognostic index risk categorisation was low risk 59(63.4%), low intermediate risk 23(24.7%), high intermediate risk 10(10.8%) and high risk 1(1.1%). There were 31(33%) patients in Group A and 62(67%) in Group B. Median follow-up was 3.9 years (range: 1.2-6.1). Overall survival at 4 years was 66.4%; for Group A 65.3% and for Group B 66.7% (p<0.4). On the basis of risk categories, overall survival was statistically significant (p<0.001) between the groups. Conclusion: International prognostic index risk categorisation had statistically significant impact on survival. However, there was no evidence of a significant survival benefit between types of chemotherapy. Further controlled trials are needed in this regard.
KW - Chemotherapy
KW - Diffuse large B cell lymphoma
KW - Extranodal
KW - Outcome
KW - Rituximab
KW - Survival
UR - http://www.scopus.com/inward/record.url?scp=84928232955&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84928232955&partnerID=8YFLogxK
M3 - Article
C2 - 25842553
AN - SCOPUS:84928232955
SN - 0030-9982
VL - 65
SP - 170
EP - 174
JO - Journal of the Pakistan Medical Association
JF - Journal of the Pakistan Medical Association
IS - 2
ER -